RxDoctor Payments Data

Kirsten Morigeau, MD

Gastroenterology · Nampa, IDNPI 1811123961

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by Medtronic at 50.4% of the total. Reporting peaked in 2019 at $1,678 and has fallen 85.4% since, to $246 in 2025.

$2,904in general payments, 2019–2025

Across 80 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$737
  • Takeda Pharmaceuticals U.S.A., Inc.$253
  • Johnson & Johnson$68
  • Zimmer Biomet$59
  • Organon$43
  • plus $278 from 12 others

What the payments were for

  • Travel & lodging$1,18641%
  • Food & beverage$1,71859%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,904 in reported general payments places this provider in the 65th percentile of 70 gastroenterology providers in Idaho.

See all gastroenterology providers in Idaho

Medicare billing

Part B allowed, 2024
$130,994
Medicare patients
365
Services billed
2,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$514,755
RemicadeInfliximab14$120,951
XifaxanRifaximin13$41,044
Mesalamine23$22,891
LinzessLinaclotide18$19,186
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates227$14,773
Budesonide DrBudesonide21$7,407
Esomeprazole Magnesium44$3,431
Ondansetron OdtOndansetron304$2,820
Colestipol Hcl22$2,662
Pantoprazole Sodium141$2,305
Famotidine112$2,079
Omeprazole92$1,507
Rabeprazole Sodium13$751
Sucralfate17$668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$68$635,70634 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$19$41,04413 claims
AbbVieLinzess$737$19,18618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 70 gastroenterology providers in Idaho.

Other gastroenterology in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →